Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.
Vocal cord cancer often leads to hoarseness, which is a common symptom of many diseases and can be easily overlooked by patients.
Alveolar rhabdomyosarcoma is a rare but very deadly childhood tumour, and for more than 40 years there have been no new advances in the treatment of this disease. Recently, a study led by Professor Anton Henssen of the Charité University of Berlin has identified a promising new treatment for the disease.
The European Union has approved the marketing of the new treatment Opdualag for the treatment of melanoma patients. New data demonstrates that the treatment resulted in the complete disappearance of tumours in 16.3% of patients, a significant reduction in tumours in 26.8% and stable disease without further progression in 18.2% of patients, giving an efficiency rate of 61.3%.
Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.
A new study shows that for a common type of skin cancer, squamous cell carcinoma of the skin, immunotherapy before surgery resulted in the complete disappearance of tumours in 50.6% of patients and more than 90% in 12.7% of patients.
A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.
For many patients after early lung cancer surgery, it is common for them to worry about recurrence. For this reason, many patients tend to undergo CT examinations more closely to ensure that they have not had a recurrence. However, a recent new study conducted by researchers from Washington University School of Medicine in St. Louis found that even with more frequent CT reviews, post-operative outcomes for lung cancer did not improve...
The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours
A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!
